Metformin Shows Promise in Reducing SARS-CoV-2 Levels in Clinical Trial

A recent clinical trial by University of Minnesota researchers found that the common diabetes drug metformin can reduce SARS-CoV-2 levels in the body, potentially lowering the risk of rebound symptoms. The study focused on standard-risk individuals and showed that metformin could decrease viral load, prevent hospitalization or death, and reduce the incidence of long COVID. Early intervention with metformin led to a 3.6-fold reduction in viral load by day 10 and decreased the likelihood of hospitalization or death by 58% within 28 days.